Sentiment-Signal
27,0
Bearisch
Composite Score (0–100)
Insider (25%)
69.6
2 Insider, 316K $ Volumen
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 13.09.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Current Report on Form 8-K supplements and amends Item 5.02 of the Current Report on Form 8-K filed on August 23, 2023 ( |
| 23.08.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | lt of, or that are associated with, the Plan. Item 5.02 Departure of Directors or Certain Officers; Election of Director |
| 02.08.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointmen |
| 23.06.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointmen |
| 16.03.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointmen |
| 22.02.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ult of, or that are associated with, the Plan. Item 5.02 Departure of Directors or Certain Officers; Election of Directo |
Stammdaten
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Unternehmen & Branche
| Name | LENZ Therapeutics, Inc. |
|---|---|
| Ticker | LENZ |
| CIK | 0001815776 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 284,4 Mio. USD |
| Beta | 2,30 |
| Dividendenrendite | 7,21 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 19,088,000 | -82,127,000 | -2.85 | 305,876,000 | 284,339,000 |
| 2025-09-30 | 10-Q | -16,700,000 | -0.59 | 210,704,000 | 193,927,000 | |
| 2025-06-30 | 10-Q | -14,912,000 | -0.53 | 217,332,000 | 206,365,000 | |
| 2025-03-31 | 10-Q | -14,619,000 | -0.53 | 201,252,000 | 192,010,000 | |
| 2024-12-31 | 10-K | 0 | -49,769,000 | -2.34 | 215,304,000 | 204,084,000 |
| 2024-09-30 | 10-Q | -10,215,000 | -0.38 | 224,007,000 | 215,280,000 | |
| 2024-06-30 | 10-Q | -10,254,000 | -0.40 | 202,639,000 | 192,921,000 | |
| 2024-03-31 | 10-Q | -16,648,000 | -3.53 | 217,322,000 | 198,167,000 | |
| 2023-12-31 | 10-K | -69,968,000 | -35.71 | 70,376,000 | -92,712,000 | |
| 2023-09-30 | 10-Q | -18,880,000 | -9.62 | 266,228,000 | -69,568,000 | |
| 2023-06-30 | 10-Q | -14,726,000 | -7.53 | 287,044,000 | -51,210,000 | |
| 2023-03-31 | 10-Q | -12,670,000 | -6.50 | 309,996,000 | -36,678,000 | |
| 2022-12-31 | 10-K | -101,052,000 | -1.84 | 321,902,000 | -24,169,000 | |
| 2022-09-30 | 10-Q | -24,682,000 | -0.45 | 334,845,000 | 316,453,000 | |
| 2022-06-30 | 10-Q | -25,936,000 | -0.48 | 353,786,000 | 338,456,000 | |
| 2022-03-31 | 10-Q | -25,835,000 | -0.48 | 378,606,000 | 361,299,000 | |
| 2021-12-31 | 10-K | -70,760,000 | -2.45 | 401,987,000 | 384,050,000 | |
| 2021-09-30 | 10-Q | -14,592,000 | -0.28 | 416,152,000 | 400,132,000 | |
| 2021-06-30 | 10-Q | -17,529,000 | -3.45 | 387,106,000 | 379,184,000 | |
| 2021-03-31 | 10-Q | -19,709,000 | -84,077,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-27 | Schimmelpennink Evert B. | Director, Officer, President, CEO and Secretary | Open Market Purchase | 28,089 | 8.95 | 251,410.59 | +219,6% | |
| 2026-03-27 | Chevallard Daniel R. | Officer, Chief Financial Officer | Open Market Purchase | 7,500 | 8.57 | 64,275.00 | +56,1% | |
| 2026-03-27 | George Jeffrey P. | Director | Open Market Purchase | 5,592 | 8.92 | 49,890.15 | +43,6% | |
| 2025-11-17 | Olsson Shawn | Officer, Chief Commercial Officer | Open Market Sale | -5,788 | 26.37 | -152,611.62 | -133,3% | |
| 2025-11-17 | Olsson Shawn | Officer, Chief Commercial Officer | Open Market Sale | -4,212 | 25.74 | -108,410.56 | -94,7% | |
| 2025-11-07 | Chevallard Daniel R. | Officer, Chief Financial Officer | Open Market Purchase | 20 | 22.71 | 454.20 | +0,4% | |
| 2025-11-07 | MCCOLLUM JAMES W | Director | Open Market Purchase | 10,500 | 22.79 | 239,278.20 | +209,0% | |
| 2025-11-07 | Chevallard Daniel R. | Officer, Chief Financial Officer | Open Market Purchase | 2,178 | 22.76 | 49,562.79 | +43,3% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.